Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-7: bb2121 Combinations in Relapsed/Refractory Multiple Myeloma
NCT04855136Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jun 2021
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of idecabtagene vicleucel in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicity rates at 28 days and Complete Response Rate at 24 months. Started Jun 2021; status: terminated.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04855136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855136.